163 related articles for article (PubMed ID: 22967380)
1. [Anti-angiogenesis effect of metronomic chemotherapy in multiple myeloma patients].
Guo LP; Zhou F; Wei W; Zhang YZ; Shi HT; Lin CH; Li L; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):457-60. PubMed ID: 22967380
[TBL] [Abstract][Full Text] [Related]
2. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
3. Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Kokonozaki M; Tsirakis G; Devetzoglou M; Kyriakaki S; Antonakis A; Vyzoukaki R; Pappa CA; Tzardi M; Alexandrakis MG
Leuk Res; 2015 Dec; 39(12):1467-72. PubMed ID: 26521986
[TBL] [Abstract][Full Text] [Related]
4. [Detection and clinical significance of platelet derived growth factor-BB and microvessel density in clear cell renal cell carcinoma].
Qi LF; Sun D; Zheng JH; Du J; Yao X
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):672-7. PubMed ID: 24332054
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
6. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
7. The role of VEGF and other parameters in tracking the clinical course in metronomic chemotherapy.
Ekinci D; Kargi A; Yalcin AD; Savas B
J BUON; 2013; 18(1):245-52. PubMed ID: 23613412
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of platelet-derived growth factor-BB and vascular endothelial growth factor as prognostic factors for patients with fulminant hepatic failure.
Takayama H; Miyake Y; Nouso K; Ikeda F; Shiraha H; Takaki A; Kobashi H; Yamamoto K
J Gastroenterol Hepatol; 2011 Jan; 26(1):116-21. PubMed ID: 21175804
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
10. Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.
Loven D; Be'ery E; Yerushalmi R; Koren C; Sulkes A; Lavi I; Shaked Y; Fenig E
Acta Oncol; 2008; 47(1):104-9. PubMed ID: 17851858
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Wang M; Liu Y; Li Y; Wu H
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
[TBL] [Abstract][Full Text] [Related]
13. VEGF-A and PDGF-BB--angiogenic factors and the stage of diabetic foot syndrome advancement.
Drela E; Kulwas A; Jundziłł W; Góralczyk B; Boinska J; Drewniak W; Gadomska G; Rość D
Endokrynol Pol; 2014; 65(4):306-12. PubMed ID: 25185854
[TBL] [Abstract][Full Text] [Related]
14. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
15. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB.
Greco C; D'Agnano I; Vitelli G; Vona R; Marino M; Mottolese M; Zuppi C; Capoluongo E; Ameglio F
Int J Immunopathol Pharmacol; 2006; 19(1):67-79. PubMed ID: 16569345
[TBL] [Abstract][Full Text] [Related]
16. [The clinical significance of angiogenesis in the bone marrow of acute leukemia patients].
Ye XJ; Wang LJ; Lin MF; Ding W
Zhonghua Nei Ke Za Zhi; 2003 Jul; 42(7):486-9. PubMed ID: 12921610
[TBL] [Abstract][Full Text] [Related]
17. Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.
Reinmuth N; Rensinghoff S; Raedel M; Fehrmann N; Schwöppe C; Kessler T; Bisping G; Hilberg F; Roth GJ; Berdel W; Thomas M; Mesters RM
Int J Oncol; 2007 Sep; 31(3):621-6. PubMed ID: 17671690
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of continuous low-dose cyclophosphamide and prednisone regimen in refractory multiple myeloma patients with severe heart failure].
Zhou F; Wei W; Ling C; Guo L; Shi H; Li L; Chen X; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):186-90. PubMed ID: 25854459
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
Yuan F; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Oncol Rep; 2015 Apr; 33(4):1753-62. PubMed ID: 25634241
[TBL] [Abstract][Full Text] [Related]
20. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
